InDevR Expands Commercial Portfolio for Coronavirus Vaccine Characterization
USA - English
Share this article
Share this article
BOULDER, Colo., Dec. 10, 2020 /PRNewswire/ InDevR, Inc., a life science tools company providing powerful analytical technologies to support the development and production of vaccines and biotherapeutics, announced commercial availability of its VaxArray® Spike Protein Kit and SARS-CoV-2 Spike Protein Standard for vaccine antigen quantification.
Of the many coronavirus vaccine candidates in development, several are based on either whole virus or recombinant spike-protein. Quantification of the spike protein concentration, or potency, at various steps in the manufacturing process is critical for characterizing vaccine performance. Many developers rely on in-house immunoassays for early protein quantification work. To streamline vaccine development, InDevR offers an off-the-shelf VaxArray kit for multiplexed quantification of spike protein based